Skip to content

Safety and Effectiveness of Wavefront-Guided LASIK Correction of Hyperopic Refractive Errors

A Prospective Study to Evaluate the Safety and Effectiveness of Wavefront-Guided Lasik Correction of Hyperopic Refractive Errors With the iDesign Advanced Wavescan Studio™ System and Star S4 IR™ Excimer Laser System

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01675479
Enrollment
167
Registered
2012-08-30
Start date
2012-12-31
Completion date
2016-10-31
Last updated
2021-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperopia

Keywords

refractive, errors

Brief summary

Demonstrate that wavefront-guided LASIK using measurements from the iDesign System is safe and effective for the treatment of Hyperopia.

Interventions

DEVICELASIK correction of hyperopic refractive errors

Surgeons will perform wavefront-guided LASIK based upon measurement obtained with the iDesign System

Sponsors

Abbott Medical Optics
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* At least 18 years of age at the time of pre-operative exam * Best Spectacle Corrected Visual Acuity (BSCVA) of 20/20 or better * Demonstration of refractive stability * Anticipated post-operative stromal bed thickness of at least 250 microns * Willing and capable of returning for follow-up examinations for the duration of the study

Exclusion criteria

* Women who are pregnant, breast-feeding, or intend to become pregnant over the course of the study * Concurrent use of topical or systemic medications that may impair healing * History of any medical conditions that could affect wound healing * History of prior intraocular or corneal surgery, active ophthalmic disease, or other ocular abnormality * Evidence of keratoconus, corneal irregularity, or abnormal topography in the operative eye(s) * Known sensitivity or inappropriate responsiveness to any of the medications used in the post-operative course

Design outcomes

Primary

MeasureTime frameDescription
Number of Eyes With a Loss of >2 Lines for Best Spectacle Corrected Visual Acuity (BSCVA)12 MonthsHypothesis: \<5% of eyes will have a loss of \> 2 lines of BSCVA at any postoperative visit, as measured using ETDRS logMAR visual acuity charts at 4 meters

Secondary

MeasureTime frameDescription
Number of Eyes With Uncorrected Visual Acuity (VA) of 20/40 or Better12 MonthsHypothesis: 85% of eyes will have uncorrected visual acuity of 20/40 or better, as measured using ETDRS logMAR charts at 4 meters

Countries

United States

Participant flow

Pre-assignment details

167 subjects were consented in the study, of which 69 subjects had one or both eyes treated for a total of 135 treated eyes.

Participants by arm

ArmCount
Wavefront-Guided LASIK
LASIK : Surgeons will perform wavefront-guided LASIK based upon measurement obtained with the iDesign System for correction of hyperopic refractive errors
69
Total69

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyLost to Follow-up11

Baseline characteristics

CharacteristicWavefront-Guided LASIK
Age, Continuous42.7 years
STANDARD_DEVIATION 11.8
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
1 Participants
Race (NIH/OMB)
Black or African American
4 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
6 Participants
Race (NIH/OMB)
White
58 Participants
Region of Enrollment
United States
69 Participants
Sex: Female, Male
Female
35 Participants
Sex: Female, Male
Male
34 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 69
other
Total, other adverse events
0 / 69
serious
Total, serious adverse events
3 / 69

Outcome results

Primary

Number of Eyes With a Loss of >2 Lines for Best Spectacle Corrected Visual Acuity (BSCVA)

Hypothesis: \<5% of eyes will have a loss of \> 2 lines of BSCVA at any postoperative visit, as measured using ETDRS logMAR visual acuity charts at 4 meters

Time frame: 12 Months

ArmMeasureValue (COUNT_OF_UNITS)
Wavefront-Guided LASIKNumber of Eyes With a Loss of >2 Lines for Best Spectacle Corrected Visual Acuity (BSCVA)2 eyes
Secondary

Number of Eyes With Uncorrected Visual Acuity (VA) of 20/40 or Better

Hypothesis: 85% of eyes will have uncorrected visual acuity of 20/40 or better, as measured using ETDRS logMAR charts at 4 meters

Time frame: 12 Months

ArmMeasureValue (COUNT_OF_UNITS)
Wavefront-Guided LASIKNumber of Eyes With Uncorrected Visual Acuity (VA) of 20/40 or Better123 eyes

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026